文献速递慢性肾脏病肾血管病与高血压

APOL1肾风险变异与SPRINT试验中心血管疾病及死亡无关联

APOL1 renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention Trial.
PubMed 文献 · Kidney Int Rep · 2017-03-31

在2568名非糖尿病高血压非洲裔SPRINT参与者中,14%携带两个APOL1肾风险变异,其基线eGFR较低且白蛋白尿和BMI较高。中位随访39个月,APOL1风险变异与主要复合心血管结局、其各组分或全因死亡均无显著关联。

要点

  • APOL1肾风险变异未增加高血压非洲裔患者的心血管事件或死亡风险。
  • 携带两个APOL1风险变异者基线肾功能较差且白蛋白尿较多。
  • APOL1与基线肾功能正常者eGFR持续下降30%仅呈趋势关联。

核心结论

  • 在高风险高血压非糖尿病非洲裔人群中,APOL1肾风险变异与突发心血管疾病无关联。

研究设计与样本

  • 研究纳入2568名非洲裔SPRINT参与者,评估APOL1肾风险变异与心血管事件、肾脏结局及全因死亡的关系。
  • 采用Cox比例风险回归模型,校正年龄、性别、非洲祖先比例和治疗组。

主要发现

  • 14%的参与者携带两个APOL1肾风险变异,这些个体基线eGFR较低且白蛋白尿和BMI较高。
  • 中位随访39个月,APOL1肾风险变异与主要复合心血管结局、其各组分或全因死亡均无显著关联(隐性或加性遗传模型)。
  • 在基线肾功能正常者中,APOL1与eGFR持续下降30%至<60 ml/min/1.73m2呈趋势关联(风险比[95%CI] 1.64[0.85-2.93];p=0.114,隐性模型)。

临床怎么用

  • 对于高血压非洲裔患者,APOL1肾风险变异状态不应作为心血管风险分层依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Relationships between apolipoprotein L1 gene (APOL1) renal-risk variants (RRVs) and cardiovascular disease (CVD) remain controversial. To clarify associations between APOL1 and CVD, 2,568 African American Systolic Blood Pressure Intervention Trial (SPRINT) participants were assessed for the incidence of CVD events (primary composite including non-fatal myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, nonfatal stroke, non-fatal acute decompensated heart failure, and CVD death), renal outcomes, and all-cause mortality. METHODS: Cox proportional hazards regression models were employed adjusting for age, sex, African ancestry proportion, and treatment group (systolic blood pressure target of <120 mm Hg versus <140 mm Hg). RESULTS: Fourteen percent of participants had two APOL1 RRVs; these individuals also had lower baseline estimated GFR and higher levels of albuminuria and BMI. After a median follow-up of 39 months, no significant association was observed between APOL1 RRVs and the primary composite CVD outcome, any of its components, or all-cause mortality (recessive or additive genetic models). APOL1 demonstrated a trend toward association with sustained 30% reduction in estimated GFR to <60 ml/min/1.73m2 in those with normal kidney function at baseline (hazard ratio [95% CI] 1.64 [0.85-2.93]; p=0.114, recessive model). CONCLUSION: APOL1 RRVs were not associated with incident CVD in high-risk hypertensive, non-diabetic African American participants in SPRINT.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Freedman BI, Rocco MV, Bates JT, et al. APOL1 renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention Trial. Kidney Int Rep. 2017. PMID: 28758155. doi:10.1016/j.ekir.2017.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。